Tandem transplantation in lymphoma

K. P. Papadopoulos; W. Noguera-Irizarry; C. S. Hesdorffer

doi:10.1038/sj.bmt.1703201

Tandem transplantation in lymphoma

K. P. Papadopoulos, W. Noguera-Irizarry, C. S. Hesdorffer

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. There is evidence for the superiority of single high-dose chemotherapy in such patients, but many still die from recurrent disease. Strategies to improve survival in these poor-risk patients include dose-intensification with high-dose chemotherapy and PBPC support, tandem autologous HDC with PBPC support, and autologous followed by non-myeloablative allogeneic transplantation. These more aggressive strategies are feasible and tolerable. Whether tandem transplantation will prove more effective than current single high-dose therapy in appropriately selected patients remains to be determined.

Original language	English (US)
Pages (from-to)	529-535
Number of pages	7
Journal	Bone marrow transplantation
Volume	28
Issue number	6
DOIs	https://doi.org/10.1038/sj.bmt.1703201
State	Published - 2001
Externally published	Yes

Keywords

Allogeneic
Autologous
Lymphoma
Tandem transplantation

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1703201

Cite this

@article{96fdeaa3b17f4022a933f1e2e88b588d,

title = "Tandem transplantation in lymphoma",

abstract = "The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. There is evidence for the superiority of single high-dose chemotherapy in such patients, but many still die from recurrent disease. Strategies to improve survival in these poor-risk patients include dose-intensification with high-dose chemotherapy and PBPC support, tandem autologous HDC with PBPC support, and autologous followed by non-myeloablative allogeneic transplantation. These more aggressive strategies are feasible and tolerable. Whether tandem transplantation will prove more effective than current single high-dose therapy in appropriately selected patients remains to be determined.",

keywords = "Allogeneic, Autologous, Lymphoma, Tandem transplantation",

author = "Papadopoulos, {K. P.} and W. Noguera-Irizarry and Hesdorffer, {C. S.}",

year = "2001",

doi = "10.1038/sj.bmt.1703201",

language = "English (US)",

volume = "28",

pages = "529--535",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Tandem transplantation in lymphoma

AU - Papadopoulos, K. P.

AU - Noguera-Irizarry, W.

AU - Hesdorffer, C. S.

PY - 2001

Y1 - 2001

N2 - The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. There is evidence for the superiority of single high-dose chemotherapy in such patients, but many still die from recurrent disease. Strategies to improve survival in these poor-risk patients include dose-intensification with high-dose chemotherapy and PBPC support, tandem autologous HDC with PBPC support, and autologous followed by non-myeloablative allogeneic transplantation. These more aggressive strategies are feasible and tolerable. Whether tandem transplantation will prove more effective than current single high-dose therapy in appropriately selected patients remains to be determined.

AB - The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. There is evidence for the superiority of single high-dose chemotherapy in such patients, but many still die from recurrent disease. Strategies to improve survival in these poor-risk patients include dose-intensification with high-dose chemotherapy and PBPC support, tandem autologous HDC with PBPC support, and autologous followed by non-myeloablative allogeneic transplantation. These more aggressive strategies are feasible and tolerable. Whether tandem transplantation will prove more effective than current single high-dose therapy in appropriately selected patients remains to be determined.

KW - Allogeneic

KW - Autologous

KW - Lymphoma

KW - Tandem transplantation

UR - http://www.scopus.com/inward/record.url?scp=0034769767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034769767&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703201

DO - 10.1038/sj.bmt.1703201

M3 - Article

C2 - 11607764

AN - SCOPUS:0034769767

SN - 0268-3369

VL - 28

SP - 529

EP - 535

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 6

ER -

Tandem transplantation in lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this